{"Abstract": [0], "Due": [1], "to": [2, 31, 124], "the": [3, 23, 33, 36, 56, 72, 76, 107, 125, 131, 147, 156], "advantages": [4], "in": [5, 43, 140], "efficacy": [6], "and": [7, 39, 75, 101, 150, 153, 158], "safety": [8], "compared": [9], "with": [10], "traditional": [11], "chemotherapy": [12], "drugs,": [13, 112], "targeted": [14, 50, 65, 88, 110, 120], "therapeutic": [15], "drugs": [16, 51, 67, 90, 122, 133], "have": [17, 52, 68], "become": [18], "mainstream": [19], "cancer": [20], "treatments.": [21], "Since": [22], "first": [24], "tyrosine": [25], "kinase": [26], "inhibitor": [27], "imatinib": [28], "was": [29], "approved": [30, 70, 132], "enter": [32], "market": [34], "by": [35, 71], "US": [37, 73], "Food": [38], "Drug": [40], "Administration": [41, 80], "(FDA)": [42], "2001,": [44], "an": [45], "increasing": [46], "number": [47], "of": [48, 58, 82, 109, 118, 160], "small-molecule": [49, 64, 87, 119], "been": [53, 69], "developed": [54], "for": [55, 143, 155], "treatment": [57], "malignancies.": [59], "By": [60], "December": [61], "2020,": [62], "89": [63], "antitumor": [66], "FDA": [74], "National": [77], "Medical": [78], "Products": [79], "(NMPA)": [81], "China.": [83], "Despite": [84], "great": [85], "progress,": [86], "anti-cancer": [89, 111, 121, 161], "still": [91], "face": [92], "many": [93], "challenges,": [94, 149], "such": [95], "as": [96, 134, 136], "a": [97, 115], "low": [98], "response": [99], "rate": [100], "drug": [102, 138], "resistance.": [103], "To": [104], "better": [105], "promote": [106], "development": [108, 159], "we": [113], "conducted": [114], "comprehensive": [116], "review": [117], "according": [123], "target": [126], "classification.": [127], "We": [128], "present": [129], "all": [130], "well": [135], "important": [137], "candidates": [139], "clinical": [141], "trials": [142], "each": [144], "target,": [145], "discuss": [146], "current": [148], "provide": [151], "insights": [152], "perspectives": [154], "research": [157], "drugs.": [162]}